Search results for Biorbic

Obsidian, Galera to advance cell therapy following reverse merger

The combined company will trade on the Nasdaq under the ticker OBX. It has also secured commitments for a private placement expected to deliver $350 million in gross proceeds.

Bioretec Ltd’s business review Q1 2026: Early Traction from Renewed Strategy

Bioretec Ltd summaries its 1Q26 revenue and strategy. The post Bioretec Ltd’s business review Q1 2026: Early Traction from Renewed Stra...

Bioretec Advances U.S. Commercialization of First-of-Its-Kind Absorbable Metal Implant

BridgeBio

BridgeBio Anonymous (not verified) Mon, 05/11/2026 - 11:23 field_thread_url https://cafepharma.com/boards/threads/bridgebio.698762/ boar...

Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain CANTON, Mass., April…

Cell therapy biotech Obsidian leverages Galera reverse merger to go public

After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a partner via a reverse merger with Obsidian Therapeutics that will ta...

Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

SpineCraft Announces U.S. FDA 510(k) Clearance of Comprehensive ORIO-3D Trabecular Interbody Platform

Westmont, Illinois, May 11, 2026, / OrthoSpineNews / – SpineCraft, a US-based spine surgery systems developer and manufacturer,…

AlloDirect Launches First Direct-to-Tissue-Bank Biologics Marketplace for Orthopedic Surgeons, ASCs, and Practices

New platform eliminates distributors from the...

Atreon Orthopedics® and RenovoDerm® Announce Merger

Positions Synthetic Portfolio as a Leading Solution for Tissue Repair and Remodeling in Substantial Markets Enables Autobiologic™ Platform…

SpineCraft Announces U.S. FDA 510(k) Clearance of Comprehensive ORIO-3D Trabecular Interbody Platform

CPC Biotech Launched to Offer a Fluid Management Component Portfolio

CPC Biotech’s solutions support a range of applications in bioprocessing operations, spanning the upstream and downstream biologic drug manufacturing process, as well as cell and g...

Bora Biologics Successfully Completes 2,000L Engineering and Scale-Up Run in San Diego, Reinforcing Commercial-Scale Rea...

Bora Biologics completes 2,000L engineering & scale-up run at its FDA-approved San Diego facility, reinforcing U.S. commercial biologics manufacturing readiness

This Startup Aims to Upend Biologic Drug Production With Implantable ‘Cell Factories’

Duracyte’s implants employ cells engineered to produce therapeutic protein, bypassing the complexities of traditional biologics manufacturing. The startup’s marriage of biotechnolo...

Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B

Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune...

Zenas BioPharma's Key Milestones And Market Context: Holding Through The BLA